Results 231 to 240 of about 130,782 (308)

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells. [PDF]

Front Immunol
Bernhardt M, Rech A, Berthold M, Lappe M, Herbel JN, Erhard F, Paschen A, Schilling B, Schlosser A.   +8 more
europepmc   +1 more source

MEK-1/MEKK-1 Inhibitor E6201 [PDF]

, 2020
openaire   +1 more source

A Case of Immunotherapy Response to BRAFV600E‐Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy

Cancer Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Introduction The recommended first‐line therapy for BRAF V600E mutant non‐small cell lung cancer (NSCLC) is a combination of dabrafenib and trametinib. Most patients respond to the initial therapy, but some show resistance in the early stages.
Yusuke Okayama, Takaaki Tokito, Shizuka Shiraishi, Reiko Takaki, Shingo Tsuneyoshi, Hiroyoshi Yamada, Mamoru Nishiyama, Yoshiko Sueyasu, Tomoaki Hoshino   +8 more
wiley   +1 more source

Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of <i>BRAF</i>-mutant advanced melanoma. [PDF]

J Manag Care Spec Pharm
Hanna KS, Palaia J, Patel D, Moshyk A, Zhou ZY, Yang F, Xin Y, Garcia-Horton V.   +7 more
europepmc   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 997-1004, April 2026.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation. [PDF]

Acta Neuropathol Commun
Steininger J, Buszello C, Oertel R, Meinhardt M, Schmid S, Engellandt K, Herold S, Stasik S, Ebrahimi A, Renner B, Thiede C, Eyüpoglu IY, Schackert G, Beissert S, Meier F, Radke J, Westphal D, Juratli TA.   +17 more
europepmc   +1 more source

Adequacy evaluation of 22‐gauge needle endoscopic ultrasound‐guided tissue acquisition samples and glass slides preparation for successful comprehensive genomic profiling testing: A single institute experience

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Objectives This study aimed to evaluate the successful sequencing rate of Foundation One CDx (F1CDx) using small tissue samples obtained with a 22‐gauge needle (22G) through endoscopic ultrasound‐guided fine needle acquisition (EUS‐TA) and to propose guidelines for tissue quantity evaluation criteria and proper slide preparation in clinical ...
Tami Nagatani, Yoji Wani, Masahiro Takatani, Soichiro Fushimi, Hirofumi Inoue, Shinichiro Hori, Kyohei Kai, Hideki Yamamoto, Tetsuya Okazaki, Maki Tanioka, Hiroyuki Okada, Akira Hirasawa   +11 more
wiley   +1 more source

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group. [PDF]

Cancer Discov
Stieglitz E, Lee AG, Angus SP, Davis C, Barkauskas DA, Hall D, Kogan SC, Meyer J, Rhodes SD, Tasian SK, Xuei X, Shannon K, Loh ML, Fox E, Weigel BJ.   +14 more
europepmc   +1 more source

Protective Effect of LGG From Lophatherum Gracile Brongn. on Alcohol‐Injured HepG2 Cells and Exploration of Potential Mechanism

eFood, Volume 7, Issue 2, April 2026.
LGG was separated from L. gracile and its hepatoprotective effect was investigated. LGG significantly reduced the mortality, ROS and MDA content in alcohol‐injured liver cells. LGG up‐regulated 156 mRNAs (63 miRNAs) and down‐regulated 1529 mRNAs (35 miRNAs).
Yi‐Long Ma, Xin Guo, Zheng‐Fang Wu, Qian‐Lan Wu, Jing Li, Tian‐Le Mao, Zhi Li, Ya‐Fang Shang, Kiran Thakur, Zhao‐Jun Wei   +9 more
wiley   +1 more source